Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Intrapulmonary PK of Funobactam (XNW4107) with Imipenem/Cilastatin in Healthy Subjects
NCT04802863Phase 1Completed
- Sponsor
- Evopoint Biosciences
- Start
- Mar 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pibozobactam in bacterial infection, sponsored by Evopoint Biosciences. Primary endpoints: Area under the concentration curve from time zero to the last quantifiable sample, Area under the concentration curve extrapolated to infinity and 5 more. Started Mar 2021; status: completed.
02
Drugs
pibozobactam
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT04802863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04802863.